Literature DB >> 12010831

Relationship of CD8(+) T cell noncytotoxic anti-HIV response to CD4(+) T cell number in untreated asymptomatic HIV-infected individuals.

JoAnn C Castelli1, Steven G Deeks, Stephen Shiboski, Jay A Levy.   

Abstract

During chronic HIV infection, asymptomatic individuals demonstrate a strong CD8(+) cell noncytotoxic antiviral response (CNAR). With the onset of symptoms or reduction in CD4(+) cell counts, CNAR decreases. Presently, it is recommended that infected individuals receive antiretroviral therapy if CD4(+) cell counts fall below 350 cells/microL. To determine whether CNAR lends support to this recommendation for initiation of antiretroviral treatment, we examined CNAR in 20 healthy, untreated, HIV-infected men exhibiting a range of CD4(+) cell numbers. Our results indicate that the asymptomatic untreated HIV-infected individuals with less than 300 CD4(+) cells/microL had a significantly lower CNAR than those with higher CD4(+) cell counts. These data on CNAR in untreated, healthy, HIV-infected individuals support the current recommendation for when to initiate antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010831     DOI: 10.1182/blood-2001-11-0078

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  Analysis of the CD8+ T cell anti-HIV activity in heterologous cell co-cultures reveals the benefit of multiple HLA class I matches.

Authors:  M Scott Killian; Fernando Teque; Ramu Sudhagoni
Journal:  Immunogenetics       Date:  2017-07-22       Impact factor: 2.846

3.  The CD8+ cell noncytotoxic anti-HIV response can be blocked by protease inhibitors.

Authors:  Carl E Mackewicz; Charles S Craik; Jay A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-06       Impact factor: 11.205

4.  Elevated CD8 counts during HAART are associated with HIV virologic treatment failure.

Authors:  Elizabeth M Krantz; Katherine Huppler Hullsiek; Jason F Okulicz; Amy C Weintrob; Brian K Agan; Nancy F Crum-Cianflone; Anuradha Ganesan; Tomas M Ferguson; Braden R Hale
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

5.  Changes in soluble factor-mediated CD8+ cell-derived antiviral activity in cynomolgus macaques infected with simian immunodeficiency virus SIVmac251: relationship to biological markers of progression.

Authors:  Vincent Dioszeghy; Kadija Benlhassan-Chahour; Benoit Delache; Nathalie Dereuddre-Bosquet; Celine Aubenque; Gabriel Gras; Roger Le Grand; Bruno Vaslin
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Natural suppression of human immunodeficiency virus type 1 replication is mediated by transitional memory CD8+ T cells.

Authors:  M Scott Killian; Carl Johnson; Fernando Teque; Sue Fujimura; Jay A Levy
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

7.  CD8+ cell anti-HIV activity rapidly increases upon discontinuation of early antiretroviral therapy.

Authors:  M Scott Killian; Jeremy Roop; Sharon Ng; Frederick M Hecht; Jay A Levy
Journal:  J Clin Immunol       Date:  2009-02-03       Impact factor: 8.317

8.  CD8(+) lymphocytes suppress human immunodeficiency virus 1 replication by secreting type I interferons.

Authors:  M Scott Killian; Fernando Teque; Robert L Walker; Paul S Meltzer; J Keith Killian
Journal:  J Interferon Cytokine Res       Date:  2013-02-12       Impact factor: 2.607

9.  Nevirapine inhibits the anti-HIV activity of CD8+ cells.

Authors:  Lianxing Liu; Lin Wang; Liusheng Huang; Vincent Siu; Fernando Teque; Francesca T Aweeka; Jay A Levy
Journal:  J Acquir Immune Defic Syndr       Date:  2013-06-01       Impact factor: 3.731

Review 10.  Elite control of HIV infection: implications for vaccine design.

Authors:  B M Baker; B L Block; A C Rothchild; B D Walker
Journal:  Expert Opin Biol Ther       Date:  2009-01       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.